CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 4 enrolled
Drug / intervention
abatacept (Orencia ®)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00886795
NCT00886795Phase 2Completed
CompareCT.gov

A Phase I/II Open-label Study to Evaluate The Safety and Efficacy of Abatacept in Subjects With Chronic Urticaria Who Have Had an Inadequate Response to Anti-histamine Therapy.

Johns Hopkins University·interventional·Posted Apr 23, 2009·Updated Jan 25, 2016

In Brief

A Phase 2 clinical trial evaluating abatacept (Orencia ®) for Urticaria. Completed, enrolled 4 participants across 1 site.

Detailed Summary

This study is being done to find out if a drug called Abatacept (Orencia ®) is safe and effective in treating people with chronic urticaria (persistent hives).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUrticaria
CountriesUnited States
CollaboratorsBristol-Myers Squibb

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 23, 2009
Enrollment StartMay 1, 2009
Primary CompletionMar 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 17.2 years ago

Interventions

abatacept (Orencia ®)drug

4 doses of abatacept administered intravenously at baseline, 2 weeks, 4 week, and 8 weeks.